open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29
Get Citation

Antiangiogenic treatment of colorectal cancer patients

Marek Z. Wojtukiewicz, Ewa Sierko, Paweł Szambora

open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29

Abstract

Colorectal cancer is one of the most frequently diagnosed malignant neoplasms in humans. Recently, introduction of antiangiogenic therapy resulted in improved treatment outcomes in colorectal cancer patients. In the article basic biological of mechanisms that influence colorectal cancer progression are presented and the results of the most important clinical trials on the efficacy of monoclonal antibody directed to the most important proangiogenic factor - vascular endothelial growth factor (VEGF) are summarized. Other options of new vessel formation inhibition, a rationale for efficacy of various forms of combined targeted therapies as well as combination of antiangiogenic treatment with cytotoxic therapy are also discussed.

Abstract

Colorectal cancer is one of the most frequently diagnosed malignant neoplasms in humans. Recently, introduction of antiangiogenic therapy resulted in improved treatment outcomes in colorectal cancer patients. In the article basic biological of mechanisms that influence colorectal cancer progression are presented and the results of the most important clinical trials on the efficacy of monoclonal antibody directed to the most important proangiogenic factor - vascular endothelial growth factor (VEGF) are summarized. Other options of new vessel formation inhibition, a rationale for efficacy of various forms of combined targeted therapies as well as combination of antiangiogenic treatment with cytotoxic therapy are also discussed.
Get Citation

Keywords

colorectal cancer; angiogenesis; bevacizumab

About this article
Title

Antiangiogenic treatment of colorectal cancer patients

Journal

Oncology in Clinical Practice

Issue

Vol 5, Supp. A (2009)

Pages

15-21

Published online

2009-04-29

Keywords

colorectal cancer
angiogenesis
bevacizumab

Authors

Marek Z. Wojtukiewicz
Ewa Sierko
Paweł Szambora

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl